Clinical TrialsBlinatumomab Replacing Chemotherapy Improves 4-Year Event-Free Survival in ... Blinatumomab Replacing Chemotherapy Improves 4-Year Event-Free Survival in ... Read Post »
Health Tidings Mergers & AcquisitionsTelix to Acquire ITM in $1.65 Billion Radiopharmaceutical Deal Telix to Acquire ITM in $1.65 Billion Radiopharmaceutical Deal Read Post »
Clinical TrialsRilzabrutinib Sustains Platelet Responses in LUNA3 ITP Study Rilzabrutinib Sustains Platelet Responses in LUNA3 ITP Study Read Post »
Clinical TrialsALKS 7290 Shows Dose-Dependent ADHD Symptom Improvements ALKS 7290 Shows Dose-Dependent ADHD Symptom Improvements Read Post »
Clinical TrialsCagriSema Shows Greater Weight Loss With Non-Inferior HbA1c Reduction CagriSema Shows Greater Weight Loss With Non-Inferior HbA1c Reduction Read Post »
Health TidingsAP02 Shows Higher Lung Exposure with Favorable Safety in IPF AP02 Shows Higher Lung Exposure with Favorable Safety in IPF Read Post »
Clinical TrialsCAPLYTA Shows Encouraging Results in Bipolar I Mania in New Study CAPLYTA Shows Encouraging Results in Bipolar I Mania in New Study Read Post »
Health TidingsCoiled Completes Enrolment in Two New AO-252 Formulation Cohorts Coiled Completes Enrolment in Two New AO-252 Formulation Cohorts Read Post »
Health TidingsFDA Accepts ARIKAYCE sNDA for Full Approval in MAC Lung Disease with Priori... FDA Accepts ARIKAYCE sNDA for Full Approval in MAC Lung Disease with Priori... Read Post »
Clinical TrialsTeva’s UZEDY Shows Real-World Benefits in Schizophrenia Teva’s UZEDY Shows Real-World Benefits in Schizophrenia Read Post »
Health TidingsPureTech’s LYT-200 Advances to Phase 2 in High-Risk MDS With FDA Fast Tra... PureTech’s LYT-200 Advances to Phase 2 in High-Risk MDS With FDA Fast Tra... Read Post »
Health TidingsBeacon’s Laru-Zova Meets Primary LLVA Endpoint in X-Linked Retinitis Pigm... Beacon’s Laru-Zova Meets Primary LLVA Endpoint in X-Linked Retinitis Pigm... Read Post »
Health TidingsOtsuka’s Centanafadine New Data Shows Core ADHD and Anxiety Benefits Otsuka’s Centanafadine New Data Shows Core ADHD and Anxiety Benefits Read Post »
Health TidingsCUE-221 Shows Durable Results in Phase 2 CSU Trial CUE-221 Shows Durable Results in Phase 2 CSU Trial Read Post »
Clinical TrialsAbbisko’s Lavengratinib Shows Early Growth Benefit in Children with A... Abbisko’s Lavengratinib Shows Early Growth Benefit in Children with A... Read Post »
Clinical TrialsTEV-‘749 Shows Durable Results in Phase 3 Schizophrenia Trial TEV-‘749 Shows Durable Results in Phase 3 Schizophrenia Trial Read Post »
Clinical TrialsHansoh’s HS-10374 Delivers Promising Phase 3 Results in Plaque Psoriasis Hansoh’s HS-10374 Delivers Promising Phase 3 Results in Plaque Psoriasis Read Post »
New Drug ApprovalFDA Grants Full Approval to Inluriyo Plus Verzenio for ESR1-Mutated Advance... FDA Grants Full Approval to Inluriyo Plus Verzenio for ESR1-Mutated Advance... Read Post »
New Drug ApprovalFDA Approves Aqneursa for Ataxia in Patients with Ataxia-Telangiectasia FDA Approves Aqneursa for Ataxia in Patients with Ataxia-Telangiectasia Read Post »
Clinical TrialsLong-Acting Antibodies Delay HIV Rebound After ART Interruption, RIO Trial ... Long-Acting Antibodies Delay HIV Rebound After ART Interruption, RIO Trial ... Read Post »
Clinical TrialsCSL Seqirus aQIVc Shows Stronger Immune Response in Phase 3 CSL Seqirus aQIVc Shows Stronger Immune Response in Phase 3 Read Post »
Health TidingsCHMP Recommends Relacorilant for Ovarian Cancer CHMP Recommends Relacorilant for Ovarian Cancer Read Post »
Mergers & Acquisitions1ST-104 Parkinson’s Drug Licensed by SK Biopharmaceuticals 1ST-104 Parkinson’s Drug Licensed by SK Biopharmaceuticals Read Post »
Health TidingsKlygefa Recommended for EU Approval in AChR-Positive Generalised Myasthenia... Klygefa Recommended for EU Approval in AChR-Positive Generalised Myasthenia... Read Post »
Clinical TrialsSanofi’s SAR443820 Fails Phase 2 HIMALAYA Trial in ALS, Ending RIPK1 Prog... Sanofi’s SAR443820 Fails Phase 2 HIMALAYA Trial in ALS, Ending RIPK1 Prog... Read Post »
New Drug ApprovalSogroya Gets Positive EU Opinion for Idiopathic Short Stature Sogroya Gets Positive EU Opinion for Idiopathic Short Stature Read Post »
Health TidingsFDA Grants Priority Review to Efzimfotase Alfa BLA for Hypophosphatasia FDA Grants Priority Review to Efzimfotase Alfa BLA for Hypophosphatasia Read Post »
Health TidingsDersimelagon Gets FDA Priority Review for EPP and XLP Dersimelagon Gets FDA Priority Review for EPP and XLP Read Post »
Health TidingsEMA Maintains Negative Opinion on MaaT013 in Acute Graft-versus-Host Diseas... EMA Maintains Negative Opinion on MaaT013 in Acute Graft-versus-Host Diseas... Read Post »
Health TidingsAltis Labs Raises $25M to Advance AI Endpoints in Oncology Altis Labs Raises $25M to Advance AI Endpoints in Oncology Read Post »
Health TidingsXenon Submits Azetukalner NDA for Focal Seizures; Pauses Psychiatry Trial E... Xenon Submits Azetukalner NDA for Focal Seizures; Pauses Psychiatry Trial E... Read Post »
Clinical TrialsBiogen Reports Positive Adolescent Data for Empaveli in C3G and IC-MPGN Biogen Reports Positive Adolescent Data for Empaveli in C3G and IC-MPGN Read Post »
Health Tidings Mergers & AcquisitionsRoche, Dualitas Launch Bispecific Antibody Discovery Deal Roche, Dualitas Launch Bispecific Antibody Discovery Deal Read Post »
New Drug ApprovalFDA Approves FAYUVI for Sanfilippo Syndrome Type A FDA Approves FAYUVI for Sanfilippo Syndrome Type A Read Post »
Health Tidings Mergers & AcquisitionsLisata Acquires Marea, Raises $225M for Cardioendocrine Drug Development Lisata Acquires Marea, Raises $225M for Cardioendocrine Drug Development Read Post »
Health TidingsAquestive Resubmits Anaphylm NDA to FDA After Positive Human Factors and PK... Aquestive Resubmits Anaphylm NDA to FDA After Positive Human Factors and PK... Read Post »
Clinical TrialsSotyktu Shows Durable Efficacy in Psoriatic Arthritis at 2 Years Sotyktu Shows Durable Efficacy in Psoriatic Arthritis at 2 Years Read Post »
Health TidingsFDA Updates IBTROZI Label With 49.7-Month DOR in ROS1+ NSCLC FDA Updates IBTROZI Label With 49.7-Month DOR in ROS1+ NSCLC Read Post »
Health TidingsNICE Recommends Enhertu for Routine NHS Use in HER2-Low Advanced Breast Can... NICE Recommends Enhertu for Routine NHS Use in HER2-Low Advanced Breast Can... Read Post »
Clinical TrialsRoche’s Lunsumio Combination Improves Progression-Free Survival in Phase ... Roche’s Lunsumio Combination Improves Progression-Free Survival in Phase ... Read Post »
New Drug ApprovalFDA Approves Kerendia for Type 1 Diabetes-Associated CKD FDA Approves Kerendia for Type 1 Diabetes-Associated CKD Read Post »
Clinical TrialsNovo’s Denecimig Shows Tolerability After Direct Switch from Emicizumab i... Novo’s Denecimig Shows Tolerability After Direct Switch from Emicizumab i... Read Post »
Clinical TrialsNovartis Discontinues Lifonebart Development in ALS After ASTRALS Phase 2 F... Novartis Discontinues Lifonebart Development in ALS After ASTRALS Phase 2 F... Read Post »
Health TidingsSironax Brain Delivery Platform Acquired by Novartis Sironax Brain Delivery Platform Acquired by Novartis Read Post »
Clinical TrialsLongeveron Laromestrocel Misses ELPIS II HLHS Endpoint Longeveron Laromestrocel Misses ELPIS II HLHS Endpoint Read Post »
Clinical TrialsRozanolixizumab Shows Limited Benefit in Severe Fibromyalgia Phase 2A Trial Rozanolixizumab Shows Limited Benefit in Severe Fibromyalgia Phase 2A Trial Read Post »
Health TidingsFDA Grants Fast Track Designation to Cesalatamig for PD-(L)1-Refractory NSC... FDA Grants Fast Track Designation to Cesalatamig for PD-(L)1-Refractory NSC... Read Post »
Health Tidings Mergers & AcquisitionsNovo Nordisk and Anthropic Partner to Accelerate AI-Driven Drug Discovery Novo Nordisk and Anthropic Partner to Accelerate AI-Driven Drug Discovery Read Post »
Clinical TrialsBoehringer Ingelheim Stops EASi-KIDNEY Trial of Vicadrostat in Chronic Kidn... Boehringer Ingelheim Stops EASi-KIDNEY Trial of Vicadrostat in Chronic Kidn... Read Post »
Health TidingsGilead Expands Lenacapavir Licenses to Support Potential Once-Yearly HIV Pr... Gilead Expands Lenacapavir Licenses to Support Potential Once-Yearly HIV Pr... Read Post »
